These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24762272)

  • 21. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of novel treatment options for patients with haemophilia.
    Ehrlich HJ; Wong WY; Ewenstein BM; Dockal M; Turecek PL; Gringeri A; Chehadeh H; Löw-Baselli A; Scheiflinger F; Reininger AJ
    Hamostaseologie; 2013; 33 Suppl 1():S36-8. PubMed ID: 24169902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.
    Muto A; Yoshihashi K; Takeda M; Kitazawa T; Soeda T; Igawa T; Sakamoto Y; Haraya K; Kawabe Y; Shima M; Yoshioka A; Hattori K
    J Thromb Haemost; 2014 Feb; 12(2):206-13. PubMed ID: 24738137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reply to 'Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors' (Haemophilia 2009; 15: 3-10).
    Hedner U
    Haemophilia; 2010 Mar; 16(2):372-3. PubMed ID: 20028420
    [No Abstract]   [Full Text] [Related]  

  • 25. New assays for monitoring haemophilia treatment.
    Shima M; Matsumoto T; Ogiwara K
    Haemophilia; 2008 Jul; 14 Suppl 3():83-92. PubMed ID: 18510527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New high-technology products for the treatment of haemophilia.
    Pipe SW; Saint-Remy JM; Walsh CE
    Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.
    Peyvandi F; Palla R; Menegatti M; Siboni SM; Halimeh S; Faeser B; Pergantou H; Platokouki H; Giangrande P; Peerlinck K; Celkan T; Ozdemir N; Bidlingmaier C; Ingerslev J; Giansily-Blaizot M; Schved JF; Gilmore R; Gadisseur A; Benedik-Dolničar M; Kitanovski L; Mikovic D; Musallam KM; Rosendaal FR;
    J Thromb Haemost; 2012 Apr; 10(4):615-21. PubMed ID: 22321862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, distribution, and excretion of 125I-labeled human plasma-derived-FVIIa and -FX with MC710 (FVIIa/FX mixture) in rats.
    Nakatomi Y; Tsuji M; Nakashima T; Gokudan S; Miyazaki H; Tomokiyo K; Ogata Y; Harano S; Matsui H; Shigaki T; Nakamura T; Mogi M
    Thromb Res; 2012 Jan; 129(1):62-7. PubMed ID: 21621824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent.
    Nakatomi Y; Nakashima T; Gokudan S; Miyazaki H; Tsuji M; Hanada-Dateki T; Araki T; Tomokiyo K; Hamamoto T; Ogata Y
    Thromb Res; 2010 May; 125(5):457-63. PubMed ID: 20080285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and supply of haemophilia products: worldwide perspectives.
    Farrugia A
    Haemophilia; 2004 Jul; 10(4):327-33. PubMed ID: 15230945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies.
    de Alarcon P; Benjamin R; Dugdale M; Kessler C; Shopnick R; Smith P; Abshire T; Hambleton J; Matthew P; Ortiz I; Cohen A; Konkle BA; Streiff M; Lee M; Wages D; Corash L
    Transfusion; 2005 Aug; 45(8):1362-72. PubMed ID: 16078927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents.
    Mehta R; Parameswaran R; Shapiro AD
    Haemophilia; 2006 Dec; 12 Suppl 6():54-61. PubMed ID: 17123395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis.
    Takeyama M; Sakurai Y; Shima M; Matsumoto T; Nogami K; Tanaka I; Takeda T; Giddings JC; Yoshioka A
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):1-7. PubMed ID: 17179819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Cabrera N; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2011 Jul; 17(4):590-6. PubMed ID: 21299747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study.
    Dargaud Y; Desmurs-Clavel H; Marin S; Bordet JC; Poplavsky JL; Negrier C
    J Thromb Haemost; 2008 Jun; 6(6):962-8. PubMed ID: 18373620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Development and Impact of Hemostatic Stewardship Programs.
    Dane KE; Streiff MB; Lindsley J; Montana MP; Shanbhag S
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):887-901. PubMed ID: 31466611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prothrombin complex concentrate (Octaplex): a Portuguese experience in 1152 patients.
    Carvalho MC; Rodrigues AG; Conceição LM; Galvão ML; Ribeiro LC
    Blood Coagul Fibrinolysis; 2012 Apr; 23(3):222-8. PubMed ID: 22450543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coagulation management.
    Grottke O
    Curr Opin Crit Care; 2012 Dec; 18(6):641-6. PubMed ID: 23090566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant activated factor VII as a universal haemostatic agent.
    Hedner U
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.